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Summary 
 
Providing a sensitive, non-invasive, cheap marker of disease activity inflammatory 
bowel disease (IBD) comprises an area of ongoing interest and unmet clinical need. In 
previous years, options included only serum CRP (poorly sensitive and specific), 
colonoscopy (invasive, costly, perforation risk, inability to view proximal small bowel), 
CT (costly, ionising radiation risk) and radiolabelled white cell scanning (costly, poor 
sensitivity).  My thesis describes a series of trials performed to establish the role of 
faecal calprotectin to define current disease activity in IBD patients. 
 
Prompted by studies demonstrating the potential role for a novel faecal marker of 
clinical utility in the context of NSAID enteropathy, we chose to investigate the role of 
this biomarker, faecal calprotectin (FC), in Crohn’s disease. To facilitate this I used 
existing cohorts and then generated new cohorts in which to address fundamental and 
clinically relevant questions of importance.  We compared FC to radiolabelled white 
cell scanning in our first study which initiated and established a mutually beneficial 
collaboration between luminal gastroenterology and clinical biochemistry. Thereafter 
we recruited a rigorously phenotyped cohort of Crohn’s disease patients in remission to 
answer two separate research questions. First, was there a significant intra-individual 
variability of FC and secondly, would FC sampling in remission predict future relapse 
over the ensuing 12 months?  Thereafter, in a new cohort, we investigated whether we 
were over-investigating new GP referrals to the GI clinic with only mildly elevated FC 
values. Finally, and most recently, we sought to investigate whether or not there was 
any correlation between serum calprotectin and FC in a new unselected GI cohort of 
patients, thereby potentially obviating the need for our patients to collect stool samples. 
 
Our data demonstrated that FC correlated well with radiolabelled white cell scanning in 
assessment of Crohn’s disease activity, thereby potentially avoiding this costly test as 
part of disease monitoring. In addition, we defined an acceptable intra-individual 
variability of FC in Crohn’s disease to support the clinical utility of one off testing 
using FC. Our prospective dataset revealed that an FC in remission can indeed stratify 
Crohn’s disease patients to estimate future relapse risk thereby allowing us to 
 8 
personalise medical therapies with more aggressive therapeutics employed in those 
with Crohn’s disease in remission but with residual high FC. The work we undertook in 
our primary care dataset revealed an extremely low yield of investigating mildly 
elevated FC and thus we developed a new shared protocol with our GP colleagues in 
which serial FC testing is recommended rather than referral to secondary care for such 
patients. Lastly, our most recent work demonstrated that there was no significant 
correlation between serum and FC in an unselected GI cohort meaning the search for a 
GI-specific serum biomarker of inflammation goes on – this is in accord with a variety 
of other chronic inflammatory diseases in which circulating biomarkers have proven 
challenging to find and especially to validate. 
 
This body of work has been presented nationally and internationally at meetings, and 
has been published in discipline relevant, peer reviewed medical journals. Moreover, it 
has supported the adoption of FC into everyday NHS GI practice. We were the first UK 
hospital to establish an NHS service for this biomarker in 2007 when we performed 
around 50 assays per month. Currently, the test is in widespread use and the Glasgow 
Royal Infirmary biochemistry lab now analyses 1400 samples per month. This has 
become an established non-invasive, cheap, sensitive marker of IBD activity in clinical 
practice, often avoiding the need for colonoscopy for the purposes of disease activity 
monitoring. This biomarker is also being used to gauge the success or failure of medical 
therapies in IBD and is a useful tool to differentiate irritable bowel syndrome from 
IBD. The clinical utility of the test has allowed GPs to triage referrals and often avoid 
referrals completely and has engaged patients in the self-monitoring of their IBD. 
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Introduction 
 
The clinical need for a sensitive, cheap, non-invasive measure of inflammatory burden 
in the GI tract is significant. Faecal biomarkers represent an attractive option in view of 
the shortcomings of the other available options in luminal gastroenterology including 
CRP (poorly sensitive and specific), radiolabelled white cell scanning (costly, poor 
sensitivity), CT scanning (costly, poorly sensitive, ionising radiation dose) and 
colonoscopy (invasive, costly, perforation risk, inability to visualise the proximal small  
bowel). 
 
Of the faecal biomarkers of inflammation available, FC has been the most studied. 
Calprotectin, first described in 1980 (Fagerhol MK 1980), is a protein found in the 
cytosol of neutrophils and macrophages composed of two subunits S100A8 and 
S100A9. It can be detected in plasma, urine, cerebrospinal fluid, faeces, saliva, synovial 
fluid and colonic biopsies (Johne B 1997)  It is stable in faeces for up to seven days at 
room temperature and has a homogenous distribution in faeces (Roseth AG 1992), 
properties which lend it to testing spot faecal samples. There has been recent emphasis 
of the involvement of the innate immune system in the pathogenesis of IBD (Kono H 
2008). Calprotectin is classed as a damage associated molecular pattern protein 
(DAMP) having antimicrobial protective properties. DAMPs are released by the innate 
immune system from damaged or activated cells, initiating and perpetuating the 
immune response. The extracellular release of calprotectin during times of cell 
stress/damage makes it an accurate marker of intestinal inflammation. 
 
Over the last 15 years, I have led a clinical research programme looking at FC in 
luminal gastroenterology. In 2002, I became interested in this faecal biomarker due to 
its potential utility in our IBD cohort at GRI. We undertook a cross sectional 
cooperative study of FC, radiolabelled white cell scanning and the CDAI in CD patients 
attending our out patients clinic (paper). Thereafter we analysed intra-individual 
variability of FC in quiescent CD (paper). Utilising the same cohort of patients, we 
prospectively followed these patients to ascertain the predictive value of FC in CD 
patients in remission (paper). Owing to concerns that we were over-investigating 
 10 
patients with mildly elevated FC referred to the GI clinic at GRI, we specifically sought 
to address this question (paper). Most recently, we investigated whether there was any 
correlation between FC and serum calprotectin in an unselected cohort of GI patients 
(paper). 
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Chapter 1 – FC in the assessment of Crohn’s disease activity (Gaya DR et al Q J 
Med 2005;98:435-441)  
 
1.1 Introduction 
The clinical assessment of CD activity is challenging and correlates poorly with 
endoscopic findings. However endoscopy is invasive, unpleasant for patients, carries 
significant morbidity and is expensive. Hence a faecal biomarker is an attractive 
alternative option. We compared radio-labelled white cell scanning (WCS), a validated 
clinical scoring system (CDAI, see appendix I) and FC in the assessment of CD 
activity. 
 
1.2 Methods 
Patients were recruited from the GI out-patient clinic at GRI with symptoms suggestive 
of a CD relapse. After signed informed consent, a CDAI was calculated for each 
patient. Subsequently a WCS and stool sample collection were done on the same day. 
Exclusions included being on oral prednisolone, a PPI, NSAID or having a positive 
stool culture or purely perianal CD.  
Samples for FC were collected and stored within 6 hours at -20̊ C and annalised by a 
commercial ELISA method (Calprest, Calprotech Ltd) as per the manufacturer’s 
instructions. WCS was performed in the nuclear medicine department of GRI using an 
established protocol. Interpreaton of the WCSs was undertaken by three experienced 
reporters who were each blinded to the CDAI and FC results.  
Statistical analyses were undertaken using Minitab version 13 (Minitab Inc) and the 
study was granted full ethical opinion by the GRI REC (01GA005). 
 
1.3 Results 
A box plot of the FC concentrations from the 35 entrants is shown in figure 1 with 
ranges from 5 – 7623 µg/ml and 85% having a raised FC. FC correlated significantly 
with mean total WCS score (r=0.73, p<0.001) (figure 2), ‘extent’ WCS score (r=0.71, 
p<0.001) (figure 3), ‘severity’ WCS score (r=0.64, p<0.001) (figure 4) and ‘combined 
extent and severity’ WCS score (r=0.71, p<0.001) (figure 5). No correlation was seen 
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between CDAI and FC (r=0.33, p=0.06) (figure 6) or mean total WCS score (r=0.21, 
p=0.24) (figure 7).  
Using ROC analysis, at a value of 100µg/g, FC had a sensitivity of 80%, specificity of 
67%, PPV of 87%, NPV of 60% in detecting CD patients with and without 
inflammation on a WCS. The accuracy of FC in correctly classifying a CD patient, as 
measured by the AOC, was 87% (figure 8). 
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1.4 Conclusion 
Our data revealed that FC correlated well with WCS in the assessment of CD activity. 
ROC analysis illustrated that a one off FC gave an accurate reflection of the extent 
and/or severity if the inflammation. Furthermore, CDAI did not correlate with either FC 
or WCS and is thus a poor surrogate for inflammatory burden in CD patients. 
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Chapter 2 – Intra-individual variability of FC in CD patients (Naismith GD et al 
Aliment Pharmacol Ther 2013;37:613-21) 
 
2.1 Introduction 
Whilst FC has been adopted into routine GI clinical practice, there are concerns 
regarding the variability of FC within the same patient. Thus clinical decision making 
based on a one off FC may be flawed. We thus investigated the reliability and 
reproducibility of FC values in CD patients in remission.   
 
 
2.2 Methods 
Between August 2010 and November 2011, CD patients attending the OPC at GRI 
were recruited with a CDAI<150. Written informed consent was obtained. Candidates 
were asked to collect stool samples for FC over three consecutive days. The study was 
approved by the West of Scotland REC (10/S0704/1). 
Stool samples were analysed according to the manufacturer’s instructions (Buhlmann) 
using the Roche faecal extraction kit.  
The consistency of FC was analysed using the intraclass correlation (ICC) of the log 
transformed FC values. The reliability was analysed using the kappa statistic. A sample 
size of 95 patients would give sufficient power to test these parameters adequately 
 
2.3 Results 
Of the 143 patients recruited, 98 submitted three stool samples suitable for analysis. 
The baseline characteristics of these patients are shown in table 1. Despite normal 
CDAIs, the entrants FC values were wide ranging albeit most had relatively low levels 
(figure 1). The ICC was 0.84 (95% CI:0.79-0.89) which reveals good overall 
consistency between the three samples for each study participant (figure 2). The 
reliability in detecting a ‘case’ of active CD is revealed by the kappa value of 0.648 
(0.511-0.769), 0.603 (0.477-0.720) and 0.732 (0.588-0.853) for FC cut offs of >50µg/g, 
>100µg/g and >350µg/g respectively (table 2). In the wider population, using an FC cut 
off of >350µg/g would be highly reliable (table 3). 
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2.4 Conclusion 
Day to day variability of FC in CD patients in remission is low. The consistency and 
reliability of the test is good, meaning a one off value can be utilised in this patient 
cohort for clinical decision making. 
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Chapter 3 – Predictive value of FC in CD patients in remission (Naismith GD et al J 
Crohns Colitis 2014;8:1022-1029) 
 
3.1 Introduction 
Crohn’s disease is characterised by relapses and remissions. Being able to predict 
which patients are at greater risk of future relapse is of major importance. We assessed 
whether an FC level in clinical remission was of clinical utility in predicting relapse 
within 12 months. 
 
3.2 Methods 
Of the 98 CD patients in remission recruited to our previous study (chapter 2), 97 were 
followed prospectively to 12 months. The primary end point was relapse within 12 
months whilst a secondary end point was relapse at any point during follow up. Patients 
were asked to contact our IBD team with any symptoms which could represent a flare 
of disease. Flare was defined as an unplanned escalation of therapy, progression of 
disease phenotype by Montreal classification or hospitalisation for emergency 
medical/surgical treatment of CD. Only patients who were lost to follow up before 12 
months were excluded from analysis. 
Ethical approval and FC analysis was identical to our previous study (chapter 2).  
The Mann-Whitney or t-test were used to test for significant differences in continuous 
variables (inl FC) between ‘relapsers’ and ‘non-relapsers’, while Fisher’s exact test was 
used for categorical variables. The sensitivity and specificity of FC to predict relapse 
was calculated and the resulting ROC curve was plotted. The resulting AOC was 
calculated to reveal the predictive power of FC regarding future relapse and the optimal 
FC cutoff (best sensitivity/specificity, PPV, NPV) was used to calculate Kaplan –Meir 
cumulative event curves for time to relapse. A Cox proportional hazards model was 
fitted to assess the impact of an FC value above or below the optimal cutoff on time to 
relapse at any point during the study. 
 
3.3 Results 
Of the 97 recruited patients, 92 were followed to the primary end point or to 12 months 
(baseline characteristics, table 1). 10 patients (12%) relapsed within 12 months and 
these patients had higher baseline median FC than those that did not (414µg/g; IQR 
259-590 versus 96µg/g; IQR 39-237; p=0.005). ROC curve analysis revealed an 
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optimal FC cutoff of 240µg/g with a sensitivity of 80%, specificity of 74.4% NPV of 
96.8% and PPV of 27.6% (figure 1). The AUC for FC to predict CD relapse at 12 
months was 77.4% (figure 1). Only two patients with an FC <240µg/g relapsed by 12 
months whilst only a minority of those with an FC >240µg/g did relapse highlighting 
the low PPV (figure 2). We plotted a Kaplan-Meir cumulative event curve to reveal 
time to relapse with clear separation between the curves in those with FC > and 
<240µg/g (figure 3). The hazard ratio of relapse with an FC >240µg/g was 12.18 (95% 
CI 2.55-58.2; p=0.002). Table 2 shows the Cox proportional hazard model of FC on 
time to relapse and shows that patients with an FC>240 is 12.18 times more likely to 
relapse within 12 months than one who does not. Also this table reveals there was no 
impact on patient demographics on time to relapse. Table 2  
 
 21 
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3.4 Conclusion 
Our dataset reveals that adults with quiescent CD with a FC <240 are unlikely to 
relapse within 12 months and we believe this should become a therapeutic target when 
assessing patients with CD at the clinic. 
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Chapter 4 –Investigatory yield mildly elevated FC in new GI referrals (Seenan JP 
et al Frontline Gastroenterology 2015;6:156-60) 
 
4.1 Introduction 
Patients are often referred from primary to secondary care for investigation of lower GI 
symptoms in the context of a mildly elevated FC. The manufacturers’ guidance of a 
normal FC may be too low for clinical practice meaning patients could be exposed to 
unnecessary investigations in this setting. We hypothesised than many such patients 
had IBS rather than IBD. We thus investigated the diagnostic yield of endoscopic, 
histological and radiological investigation in patients aged <50 presenting with new 
lower (non-‘alarm’) GI symptoms and a mildly elevated FC (100-200µg/g). 
 
4.2 Methods 
All patients with an FC 100-200µg/g were identified from our GRI biochemistry 
database between 2009-2011. Patients aged 16-50 attending the GI OPC with new 
lower GI symptoms were identified from the EPR. Subjects were excluded if they were 
taking NSAIDS, had IBD, positive stool culture, ‘alarm’ symptoms (weight loss, rectal 
bleeding) or anaemia. Further investigations were at the discretion of the managing 
consultant gastroenterologist. The latter information was recorded from the EPR. 
 
4.3 Results 
In all, 161 patients (103 females) were identified who met the inclusion criteria. 
Baseline demographics and presenting symptoms are shown in table 1. The mean age 
was 37.3 years with a mean FC of 147µg/g. The mean duration of follow up was 172.4 
weeks. The main presenting complaint was diarrhoea in 98 (60.9%) and abdominal pain 
in 63 (39.1%). A total of 398 endoscopic, radiological and histological investigations 
were undertaken in 141 patients with an average of 2.8 investigations per patient (table 
2). A total of 131 colonoscopies were undertaken with abnormalities detected in only 
24 (18.3%). In patients with a macroscopically normal upper GI endoscopy and 
colonoscopy, the diagnostic yield of further investigations was only 7.3%.  
The NPV of an FC 100-200µg/g in this cohort was 86.7% for any pathology and 97.5% 
for significant luminal pathology (IBD, advanced adenoma or colorectal cancer). IBD 
was the final diagnosis in only 4 patients (2.5%) and IBS in 49.7%. 74% of the patients 
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were deemed not to require long term secondary care GI follow up. All diagnoses made 
are revealed in figure 1. 
 
Table 1: Patient Demographics 
Mean Age 37.3 years 
Sex Male 58 (36%) Female 103 (64%) 
Primary Symptom Abdominal Pain 63 (39.1%) Diarrhoea 98 (60.9%) 
Secondary Symptom 
Abdominal Pain 46 (28.6%) 
Diarrhoea 30 (18.6%) 
Constipation 3 (1.9%) 
Mean Faecal Calprotectin 147 µg/g 
 
 
 
 
Table 2: Investigations Performed and Diagnostic Yield 
Investigation Number Yield 
 All  398 13.3% 
Colonoscopy 131 18.3% 
Excluding Colonoscopy 267 10.9% 
TI/Colonic Biopsies 119 7.6% 
Barium Meal and Follow-through 16 6.3% 
CT 19 5.3% 
MRI Small Bowel 19 16.7% 
Capsule Endoscopy 12 8.3% 
Upper Gastrointestinal Endoscopy 47 27.7% 
Distal Duodenal Biopies 36 2.8% 
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Figure 1: Pie chart of diagnoses 
 
 
4.4 Conclusion 
In adults <50 years of age with new non-‘alarm’ GI symptoms, The NPV of an FC of 
100-200µg/g is high in excluding significant pathology. These patients often have a 
functional diagnosis and the yield of investigations is extremely low. We suggest that 
the manufacturers’ cut-off of <50µg/g is too low for use in clinical practice and that 
repeat FC testing in this cohort, rather than invasive GI investigations, would be a more 
pragmatic approach. 
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Chapter 5 – Assessment of FC compared to serum calprotectin in GI patients 
(McCann RK et al Clinical Biochem 2017 in press) 
 
5.1 Introduction 
 
5.2 Methods 
Between July and October 2015, in and outpatients within the adult GI service at GRI 
who submitted a stool sample for FC analysis were prospectively identified. Those 
patients who also had a serum sample obtained within 24h of stool sample collection 
were identified and the sample stored at -80C for batch analysis of CRP and serum 
calprotectin. The project was approved by the West of Scotland REC (14/WS/1035). 
Both serum and FC were analysed using a Buhlmann quantitative ELISA as per the 
manufacturer’s instructions. CRP was measuserd on Architect 8000 (Abbott).  
Statistical analysis was performed using MedCalc software (version 15.4). 
 
5.3 Results 
109 patients were recruited. 68 (62%) were female. The mean age was 51 years (range 
18-93). The indications for testing FC were assessment of IBD activity (69, 63%) and 
assessment of chronic diarrhoeal symptoms (40, 37%). 
Mean SC in this group of patients was 6.67 µg/mL (range: 1.06 – 24.00 µg/mL).  This 
assay is linear up to 24.00 µg/mL and for the purpose of the statistical analysis, any 
results greater than 24.00 µg/mL were arbitrarily assigned a value of 24.00 µg/mL.  
Mean FC was 362.72 µg/g (range: 30 - 1800 µg/g).  This assay is linear between 30 and 
1800 µg/g and any results less than 30 or greater than 1800 were arbitrarily assigned 
values of 30 and 1800 µg/g, respectively, for statistical purposes.  Mean CRP was 15.3 
mg/L (range: 1.0 – 126 mg/L) and any CRP result less than 1.0 mg/L was arbitrarily 
assigned a value of 1.0 mg/L for statistical analysis.   
The log transformed correlation datasets are illustrated on figures 1, 2 and 3 for SC/FC, 
SC/CRP and FC/CRP respectively. Correlations were expressed as intraclass 
correlation coefficients (ICC) and were calculated following logarithm transformation 
of the data (Table 1).  The closer the ICC is to 1 the better the agreement.   
Excluding data outside the linear range of the three assays created a patient cohort of 73 
patients.  When the statistical analysis was repeated with this smaller cohort it had no 
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significant effect on the overall statistical outcome thus indicating that assigning 
arbitrary values did not create a bias in the dataset.  
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Figure 1: Serum Calprotectin vs Faecal Calprotectin  
All data was log transformed.  Serum calprotectin results (y-axis) were plotted against 
faecal calprotectin results (x-axis). Trendline, equation and R2 value are depicted on the 
graph.   
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Figure 2: Serum Calprotectin vs CRP 
All data was log transformed.  Serum calprotectin results (y-axis) were plotted against 
CRP results (x-axis). Trendline, equation and R2 value are depicted on the graph.  
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Figure 3: Faecal Calprotectin vs CRP 
All data was log transformed.  Faecal calprotectin results (y-axis) were plotted against 
CRP results (x-axis). Trendline, equation and R2 value are depicted on the graph.   
 
 
 
 
Dataset with 109 patients 
ICC 95% CI 
SC compared 
with FC 0.10 -0.09 – 0.28 
SC compared 
with CRP 0.18 -0.01 – 0.35 
FC compared 
with CRP 0.18 -0.01 – 0.35 
 
Table 1: Correlations between serum calprotectin, faecal calprotectin and CRP 
 
5.4 Conclusion 
As a serum marker of intestinal inflammation, serum calprotectin is unlikely to be of 
clinical utility and the search for a serum maker with a similar profile to FC continues. 
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10. Discussion 
 
10.1 METHODOLOGICAL ASPECTS OF FC TESTING 
 
After the publication of the first method of FC analysis by ELISA in 1992 (Roseth AG 
1992), numerous kits from several competing companies have appeared for the 
commercial analysis of FC. There is a lack of standardisation of the assay leading to 
significant inter-assay variability (Whitehead SJ 2013) and the ‘normal’ range is 
debated and unlikely to be transferrable between the different assays (Lin JF 2014). 
Indeed recent guidance from NICE highlights that further research was needed before 
and recommendation could be made about a specific cut off could be made (NICE 
guidance 2013). 
 
More recently, point of care testing has been developed to facilitate self management of 
IBD at home (Coorevits L 2013, Lobaton T 2013). Also smart phone technology has 
been utilised allowing digital analysis and measuring of the FC result which can be sent 
directly to the secondary care team (Vinding KK 2016). 
 
In terms of intra-individual variability of FC analysis, we have shown good agreement 
between three samples over consecutive days in CD patients (chapter 2). Recently it has 
been shown that there is variability in FC depending on the time of day of FC sampling 
in UC patients and thus testing the first stool of the day has been recommended (Lasson 
A 2015). Also the authors noted that storage of FC samples for more than 3 days at 
room temperature is not advisable due to a decline of FC level in samples stored to 7 
days.  
 
10.2 FAECAL CALPROTECTIN IN THE DIAGNOSIS OF IBD/IBS 
 
The diagnosis of IBD has historically been based on a combination of clinical history 
and examination, blood parameters, radiology and endoscopy. The addition of a faecal 
biomarker able to reduce the need for invasive endoscopic procedures or exposure to 
radiation is advantageous. 
 
 34 
In a study of 110 patients attending for colonoscopy for the investigation of chronic 
diarrhoea showing that increased faecal calprotectin levels were significantly 
(P=0.0001) associated with the presence of colorectal inflammation (CD, UC, 
microscopic colitis or diverticulitis)(Limburg PJ 2000).  Within the colonic 
inflammation subgroup, calprotectin concentrations were highest amongst subjects with 
IBD.  The negative predictive value of faecal calprotectin in this dataset was 93%. A 
large metaanalysis of studies supports the use of FC as a screening tool for organic 
disease and in determining the need for further investigations (van Rheenan PF 2010). 
In this regard NICE recommended its use in primary and secondary care in adults with 
recent onset lower gastrointestinal symptoms, where cancer is not suspected 
(considering factors such as age), and for whom specialist assessment is being 
considered (NICE guidance 2013). 
 
IBD and irritable bowel syndromes (IBS) can present in a similar clinical fashion with 
symptoms such as diarrhoea and abdominal pain.  Routine colonoscopy in these 
patients is costly, invasive and has associated morbidity and mortality.  Serum markers 
of inflammation such as C reactive protein (CRP) and erythrocyte sedimentation rate 
(ESR) in isolation are not sufficiently sensitive or specific for the diagnosis of 
inflammatory bowel disease (Tibble J 2000) The use of faecal calprotectin to 
distinguish between IBD and IBS has been analysed in several studies. In 2000 Tibble 
presented results of a prospective study of 220 consecutive patients in whom the 
principal differential diagnosis was that of either IBS or CD.  They excluded patients 
with UC on sigmoidoscopy and biopsy. A diagnosis of CD was made from a 
combination of radiological, endoscopic and histological investigations. A diagnosis of 
irritable bowel syndrome was made on basis of normal investigations and a compatible 
history fulfilling the ROME criteria. All patients subsequently diagnosed with CD had 
significantly higher faecal calprotectin concentrations than those with IBS. The 
investigators found that using a cut-off point of 30 mg/L faecal calprotectin had a 100% 
sensitivity and 97% specificity in discriminating between active Crohn’s disease and 
IBS.  
 
Schoepfer (Schoepfer AM 2008) looked at the accuracy of faecal biomarkers alone and 
in combination with the IBD antibodies, antineutophil cytoplasmic antibody (ANCA) 
and anti-Saccharomyces Cerevisiae manna antibody (ASCA), in discriminating IBD 
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from IBS. They found that the overall accuracy of faecal calprotectin for discriminating 
between IBD and IBS was 89% (sensitivity 83%, specificity 100%). There was only a 
marginal increase in overall accuracy when faecal calprotectin was combined with IBD 
antibodies to 91%. 
 
Faecal calprotectin has been studied as a tool to predict abnormal small-bowel 
radiology (Dolwani S 2004.  The study looked at 73 consecutive patients attending for 
small bowel follow through whose presenting symptoms were consistent with a 
possible diagnosis of IBD.  The control group consisted of 25 patients with IBS, 25 
normal volunteers and 25 patients with active CD. A faecal calprotectin level above 
60µg/g predicted all abnormal barium follow through results. The negative predictive 
value of a single calprotectin result below 60 µg/g of stool was 100% compared with 
91% each for erythrocyte sedimentation rate cut off of 10 mm and C-reactive protein of 
6 mg/L. Somewhat in contrast to this Sipponen (Sipponen T 2012) found that faecal 
calprotectin had a low utility for predicting the presence of small bowel CD on wireless 
capsule endoscopy, sensitivity was low at 59% with a moderate specificity of 71% 
using a cut-off of 50µg/g. 
 
A meta-analysis analysed 30 prospective studies comparing the diagnostic precision of 
faecal calprotectin against a histological diagnosis (von Roon AC 2007). Summary 
receiver operating characteristic curve analysis showed a sensitivity of 0.95 (95% CI 
0.93-0.97), specificity of 0.91 (95% CI 0.86-0.91), and an area under the curve (AUC) 
of 0.95 for the diagnosis of IBD. The diagnostic precision of faecal calprotectin for IBD 
was higher in children than adults with better accuracy at a cut-off level of 100 µg/g 
versus 50 µg/g. This meta-analysis also showed that faecal calprotectin was superior to 
CRP, ESR, ASCA, pANCA and anti-Escherichia coli outer membrane porin C antibody 
in diagnosis of IBD. 
 
Thus it can be stated that a normal faecal calprotectin result, in the absence of ‘red flag’ 
symptoms and in the context of positive Rome criteria, is associated with a high 
likelihood of subsequent non-organic diagnosis and further endoscopic or radiological 
evaluation may be avoided in such patients.  A meta-analysis published in 2010 to 
assess whether the use of faecal calprotectin reduces the number of unnecessary 
endoscopic procedures in the investigation of suspected IBD showed that screening 
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with faecal calprotectin would result in a 67% reduction in the number of adults 
requiring endoscopy.  The downside of this screening strategy is delayed diagnosis in 
6% of adults because of a false negative test result (van Rheenan PF 2010). Our own 
data suggests that a mildly elevated FC in patients <40 is most likely to yield a 
diagnosis of IBS and invasive GI investigations could be avoided (chapter 4). 
 
Previous studies suggest that the trend in FC can be a useful indicator of the likelihood 
of significant pathology. Demir et al (Demir OM 2013) examined patients referred from 
primary to secondary care with GI symptoms in whom a FC had been checked. 2663 
patients were included. They looked in more detail at patients with a 'minimally 
elevated' FC (50-150µg/g) and those with higher levels (150-3000µg/g) who underwent 
repeat FC testing after an interval of 6-8 weeks. In the higher FC cohort, there were 13 
new cases of IBD with a mean increase in FC from 933 to 1666µg/g. In 66 patients 
with a 'minimally elevated' FC, none developed IBD during the 2 years of follow-up 
and the mean FC fell from 88 to 65µg/g. Similarly in the study by Zayyat et al (Zayyat 
R 2011), in 90% (9/10) of the patients who were ultimately diagnosed with IBD  a 
repeat FC had increased.  
 
Furthermore, a small study by Mohammed et al (Mohammed N 2012) demonstrated 
that after initial negative radiological or endoscopic GI investigations, longer term 
follow-up of patients with elevated FC <225µg/g failed to identify significant 
pathology.  67 patients were followed for 3 years with no patients found to have IBD 
during subsequent review. Recent work by D'Haens et al (D'Haens G 2012) in IBD 
patients supports the observation that FC levels of this magnitude are not associated 
with significant mucosal inflammation. In their study which examined 126 patients 
with IBD, a FC <250µg/g was associated with mucosal healing, predicting endoscopic 
remission (CDEIS ≤ 3) with 94.1% sensitivity. 
 
Faecal calprotectin appears to better reflect disease activity in UC rather than CD 
(Costa F 2005) but faecal calprotectin has not been found to be useful in distinguishing 
UC from CD. Quail et al (Quail MA 2009) looked at faecal calprotectin concentrations 
in Scottish children with a diagnosis of IBD; there was no statistical difference in 
 37 
calprotectin concentrations between CD and non-Crohn’s patients (UC or IBD type 
unspecified – IBDU). 
 
10.3 FAECAL CALPROTECTIN IN ASSESSMENT OF DISEASE ACTIVITY 
AND RESPONSE TO TREATMENT 
 
In IBD, the presence of active gut inflammation is associated with migration of 
leucocytes, including neutrophils, to the gut mucosa (Vermeire S 2006). As a result the 
faecal stream contains increased levels of these inflammatory proteins including 
calprotectin. Faecal calprotectin has been shown to differentiate quiescent from active 
disease in both patients with CD and UC (Sipponen T 2008, Langhurst J 2005, Xiang 
JY 2008). Correlation of faecal calprotectin tends to be higher with endoscopic activity 
than clinical activity indices (Schoepfer AM 2010) and indeed some studies have 
demonstrated no significant correlation between faecal calprotectin and clinical indices 
(Gaya DR 2005, Jones J 2008). In general faecal calprotectin correlates better with 
colonic CD rather than ileal disease (Sipponen T 2008) and an inflammatory rather than 
a structuring/penetrating phenotype (Sipponen T 2008). Sipponen et al showed that in 
active disease (Crohn’s disease endoscopic index of severity, CDEIS ≥3), faecal 
calprotectin concentrations were significantly higher in colonic than in ileal CD. Also, 
in limited ileal disease faecal calprotectin failed to correlate with endoscopic activity. 
 
In UC Ricanek et al (Ricanek P 2011) showed that the median faecal calprotectin 
concentration was higher in patients with extensive and left sided disease distribution 
compared with proctitis (740µg/g, 2106µg/g, 86µg/g respectively; p=0.007 and 
p=0.009). There was no significant difference in faecal calprotectin concentration 
between extensive and left sided disease distribution. 
 
There have been several studies looking at the use of faecal calprotectin to predict or 
monitor response to treatment. In a study (Wagner M 2008) looking at 11 patients with 
relapsing IBD (11 CD and 27 UC) faecal calprotectin was analysed at inclusion and 
after 8 wk of treatment (end of study). Treatment was individualised medical therapy. A 
normalised faecal calprotectin concentration at 8 weeks predicted a complete response 
in 100% patients. There was a significant decline in faecal calprotectin levels (P<0.001) 
in patients with UC responding to treatment defined as normalisation of clinical and 
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endoscopic scores.  Within the small subgroup of patients with CD although 81% of 
patients achieved a complete clinical response defined clinically as a Harvey Bradshaw 
Index (HBI) ≤5 there was no significant decline in calprotectin levels. This study was 
limited by small numbers and also the lack of endoscopic evidence of disease activity 
or remission in CD patients, it is possible that these patients had ongoing subclinical 
inflammation. In fact it has been shown that in patients with steroid induced clinical 
remission faecal calprotectin levels can remain elevated (Sipponen T 2010). This 
finding is in keeping with earlier studies showing incomplete mucosal healing in 
patients treated with corticosteroids (Modigliani R 1990). Sipponen et al (Sipponen T 
2010) were able to show a significant decrease in faecal calprotectin (P=0.005) in 
patients with CD who responded both clinically and endoscopically (using CDEIS) to 
an individualised escalation of treatment. There was no significant change in faecal 
calprotectin concentration in patients without endoscopic response. 
 
Faecal calprotectin may be able to predict colectomy in patients with acute severe UC. 
Ho (Ho GT 2009) showed that in patients with acute severe UC requiring inpatient 
treatment with intravenous corticosteroids faecal calprotectin was significantly higher 
in patients who failed to respond to medical therapy and required colectomy than those 
who did not (P=0.04). The area under the curve was 0.65 (P=0.04) for faecal 
calprotectin to predict colectomy with a maximum likelihood ratio of 9.23 at a cut-off 
of 1922.5 μg/g (specificity of 97.4%). Overall in the study faecal calprotectin 
concentrations were high with 86% of patients having levels of >500 μg/g (median 
1020 μg/g). 
 
Faecal calprotectin can be used to monitor response to biological therapy. Palmon 
(Palmon R 2006) showed that faecal calprotectin concentration decreases significantly 
at week 2 after an infliximab (IFX) infusion in 17 patients with CD on maintenance 
IFX therapy.  Calprotectin levels were noted to rise back to baseline values by week 4 
again despite a low median HBI. There was no endoscopic assessment of disease 
activity in this study. The rise in faecal calprotectin at week 4 may once again indicate a 
subclinical recurrence of mucosal inflammation. Sipponen (Sipponen T 2008) assessed 
the role of faecal calprotectin in monitoring clinical, using the Crohn’s disease activity 
index (CDAI) and endoscopic (CDEIS) response to anti-TNF-α therapy (infliximab or 
adalumimab) in 15 patients with CD. Following 12 wk of treatment faecal calprotectin 
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levels declined significantly from baseline level (P=0.001) and changes in faecal 
calprotectin correlated to endoscopic appearances as scored using CDEIS (Spearman’s 
rank correlation = 0.561, P=0.03) suggesting that faecal calprotectin is a useful non-
invasive marker of mucosal response to anti-TNF-α treatment. 
 
10.4 PREDICTING MUCOSAL HEALING 
 
Historically clinical practice has considered interpretation of symptoms and the use of 
scoring systems such as the CDAI, HBI and the Rachmilewitz ulcerative colitis activity 
index (CAI) to determine treatment success in IBD. These indices however tend to 
reflect patient well-being and quality of life rather than the degree of mucosal 
inflammation (Gaya DR 2005).  In both CD and UC there is evidence that mucosal 
healing is associated with sustained remission and reduced need for surgery (Froslie KF 
2007, Baert F 2010) and following ileal resection the endoscopic appearance of the 
neoterminal ileum mucosa at 1 year post surgery has been shown to predict 
symptomatic relapse (Rutgeerts P 1999). Thus mucosal healing is evolving into the new 
goal of IBD treatment.  
  
Roseth (Roseth AG 2004) demonstrated that normalisation of faecal calprotectin 
concentration corresponds to endoscopic mucosal healing.  17 patients with CD and 28 
with UC clinically in remission who had faecal calprotectin concentrations of <50 mg/L 
underwent endoscopic assessment of their lower GI tract and macroscopic mucosal 
appearances were assessed.  Biopsies were also taken to assess histological 
inflammation. All but one of these patients with faecal calprotectin <50 mg/L had 
inactive mucosal disease on colonoscopy. 
 
Several subsequent studies have on to show that concentration of faecal calprotectin 
correlates with both histological and endoscopic disease activity in IBD (Langhorst J 
2008, Sipponen T 2008, Jones J, Roseth AG 1997). Furthermore, several of the studies 
included in table 1 show that correlation of faecal calprotectin with endoscopic 
appearances is stronger than correlation with clinical indices (D’Haens G 2012, 
Sipponen T 2008, Jones J 2008). 
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However, Denis (Denis MA 2007) failed to find a significant correlation between 
CDEIS and faecal calprotectin concentration. This was a small study of 28 patients with 
CD who had CDAI>150 but a normal serum CRP. This lack of correlation may reflect 
the population studied as more than half of the patients had isolated ileal disease and 
overall disease activity was low (median CDEIS 3.4). 
 
Interestingly one study in paediatric patients with IBD showed that calprotectin 
concentration correlated more closely with histological inflammation rather than 
endoscopic findings suggesting that faecal calprotectin may be more sensitive than 
macroscopic endoscopic appearances in evaluating disease activity status (Bunn SK 
2001). 
 
10.5 USE OF FAECAL CALPROTECTIN TO PREDICT RELAPSE 
 
Being able to identify patients at high risk of relapse, and those with sub-clinical 
intestinal inflammation, may allow adjustment of their treatment strategy thus 
preventing clinical relapse.  A non-invasive method of identifying this would reduce 
cost and risk of morbidity and mortality to patients. As sensitivity and specificity of 
serum markers of inflammation correlate poorly with intestinal inflammation their 
ability to predict disease relapse is poor (Tibble JA 2000, Langhorst J 2008). Several 
studies have looked at the use of faecal calprotectin to predict relapse in patients with 
IBD and have demonstrated significant differences in faecal calprotectin concentration 
in relapsers compared with non-relapsers (Naismith G 2012, Laharie D 2011, Kallel L 
2010, Gisbert JP 2009). A recent study of patients with endoscopic remission, showed 
that FC was a better predictor of future relapse than microscopic inflammation in 
biopsies (Mooiweer E 2015). Serial measurement of FC in IBD patients in clinical and 
endoscopic remission has been shown to rise before clinical relapse (Molander P 2015). 
This study evaluated patients stopping anti-TNF-α therapy with an initial FC <100ug/g, 
with monthly calprotectin for six months, and then bimonthly. Calprotectin rose a 
median of 94 (13-317) days before clinical symptoms. This implies that early 
reintroduction of treatment could be made before symptoms recur, on the basis of rising 
calprotectin, but there is still inadequate data to support such use of FC. Interestingly, 
faecal calprotectin appears less useful for predicting relapse in patients with ileal CD 
compared with patients with UC or colonic / ileocolonic CD (D’Inca R 2008, Garcia-
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Sanchez V 2010).  
 
The major outlier in the literature on this topic is the study by Laharie (Laharie D 2011) 
which looked at the use of faecal calprotectin to predict relapse specifically in 65 
patients with CD treated with infliximab induction regimen and then maintained on 
immunomodulator alone. There was no significant difference in faecal calprotectin 
concentration between those patients who relapsed by 14 weeks post induction and 
those who did not even when the analysis was restricted to patients with pure colonic 
disease. No endoscopic evaluation was performed after infliximab induction so 
although the study did show a median drop in faecal calprotectin concentration of 
340μg/g following induction there may have been ongoing subclinical inflammation.  
Another limitation of this study is that disease relapse was defined on clinical grounds 
alone. 
 
Mao (Mao R 2012) performed a meta-analysis of the predictive capacity of faecal 
calprotectin in IBD relapse. Analysing 6 studies they found a pooled sensitivity of 78% 
and specificity of 73%. Capacity to predict relapse was comparable between CD and 
UC. Due to the small number of patients the predictive value of faecal calprotectin in 
ileal only CD patients was not assessed.  
 
Overall, elevated FC in patients in remission is currently used as a screening test to 
prompt restaging of CD by colonoscopy and/or MRI scanning by clinicians. As it is an 
insensitive test, being raised in many inflammatory bowel pathologies, therapeutic 
intervention on the basis of a rasied FC  alone in CD cannot be recommended.  
 
10.6 DETECTION OF POST-OPERATIVE CD RELAPSE 
 
More than 80% of CD patients require surgery within 10 years of diagnosis and by 3-5 
years after surgery around a third of patients will have had a clinical relapse (Bernell O 
2007).The role of faecal calprotectin in predicting post-surgical recurrence of CD has 
been assessed.  One study assessed 39 patients with CD undergoing bowel resection 
(Orlando A 2006).The majority of patients (67%) had ileocolonic disease. 
Measurements of faecal calprotectin, CDAI and ultrasound examination were 
performed at 3 months post surgery. Endoscopy was performed at 1 year regardless of 
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patient symptoms and was considered the ‘gold standard’ for recurrence of disease.  All 
patients were clinically in remission at 3 months. Using a cut-off level of 200mg/L, in 
predicting endoscopic post-surgical recurrence, faecal calprotectin has a sensitivity of 
63% and specificity of 75% leading the authors to suggest that patients with elevated 
faecal calprotectin levels at 3 months post surgery should be assessed endoscopically 
for early recurrence. 
 
Lamb (Lamb CA 2009) prospectively followed 13 patients for 12 months post 
ileocaecal resection for symptomatic CD. Faecal calprotectin was seen to normalise 
after uncomplicated surgery at 2 months and remained within normal limits in 8 
patients who remained clinically in remission. In the remaining 5 patients there was an 
increase in faecal calprotectin concentration after initial normalisation associated with 
disease recurrence or post operative intra-abdominal collections. The authors’ 
conclusion from this small number of patients was that patients with low levels of 
faecal calprotectin after resection who had symptoms were unlikely to have mucosal 
inflammation. It should be pointed out thought that there was no scheduled endoscopic 
evaluation of the gut mucosa during the 12 month follow up period. Such datasets have 
recently been replicated in independent cohorts (Wright EK 2015). 
 
In the POCER trial (De Cruz P 2015), a prospective study to determine optimal medical 
management of post-operative Crohn’s, a faecal calprotectin >100mcg/g indicated 
endoscopic recurrence with a sensitivity 0.89 and NPV 91%, potentially allowing 
avoidance of colonoscopy in 41% of patients. 
 
10.7 USE OF FAECAL CALPROTECTIN TO AID DECISIONS OF 
WITHDRAWAL OF TREATMENT IN IBD 
 
When and in which patients it is appropriate to withdraw anti TNF alpha therapy is 
hotly debated and driven by costs and concerns about long term safety. Faecal 
calprotectin levels may assist in this decision making. Louis et al (Louis E 2012) 
published results of a prospective study (STORI) of CD patients who had been in 
steroid free remission on infliximab and thiopurine or methotrexate for at least six 
months. Relapse after infliximab withdrawal was associated with various risk factors 
including a faecal calprotectin concentration of ≥300µg/g.  Other risk factors for relapse 
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identified on multivariate analysis included male sex, absence of surgical resection, 
leucocyte counts >6 × 109/L, haemoglobin ≤145 g/L and hsCRP ≥5.0 mg/L. Patients 
with no more than 2 of the above risk factors had a reduced risk of relapse within 1 year 
(15% compared with 43.9% overall). A low faecal calprotectin can thus be used to aid 
decision-making about stopping therapy, although once again there is little data on 
relevant calprotectin thresholds, which most likely vary between patients and assays. 
 
10.8 LIMITATIONS OF FC IN LUMINAL GASTROENTEROLOGY 
 
A number of different commercial calprotectin assays are available and some concerns 
have been raised about inter-assay variability in the literature, which is due, in part, to 
a lack of assay standardisation (Lahere D 2014). The derivation of a nationally agreed 
normal range and an “intermediate” level is thus an area of concern due to this 
between-assay variability (van Room AC 2007, Henderson P 2014, Dhaliwal A 2014, 
Kristensen V 2015). Indeed the NICE committee highlighted the different thresholds 
for interpreting faecal calprotectin results and concluded that there was a need to 
undertake further research before a recommendation on a particular cut‑off could be 
nationally agreed (NICE guidance 2013). 
 
There is insufficient evidence to rely on faecal calprotectin to diagnose colorectal 
cancer or polyps. It should not therefore be used to evaluate older patients (with a cut-
off varying between 40 and 50 years, best determined by local audit data) where 
colonoscopy is mandated as part of established care pathways to exclude colorectal 
neoplasia (van Room AC 2007). 
 
When used in primary care to identify patients with altered bowel habit who require 
colonoscopy for possible IBD, it is clear that use of the upper limit of the ‘normal 
range’ for assays, (usually 50ug/g stool) as the threshold for referring for colonoscopy, 
will result in large numbers of unnecessary procedures. Several authors, including 
NICE, have proposed the role of an intermediate range of faecal calprotectin for values 
that are above the reference range, but not clinically significant in assessing possible 
IBD (Seenan JP 2015). This is perhaps justified by the need to balance sensitivity and 
specificity. An indeterminate range could include values from 50, to as much as 
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200ug/g stool (Seenan JP 2015). The setting of a level above which colonoscopy is 
needed should be determined locally based on audit data, quality assurance processes 
and in conjunction with clinical assessment. A higher threshold will result in fewer 
investigations, but more risk of missing IBD. A lower threshold will result in fewer 
missed diagnoses (increase sensitivity), but lead to more unnecessary investigations 
(reduce specificity). It has been suggested that specificity could be improved by repeat 
testing for patients with results in the indeterminate range, assuming that patients with 
IBD will have persistently raised or rising calprotectin (Zayyat R 2011). There is 
currently inadequate data to recommend re-testing of patients in this way. The NICE 
review emphasised the need for research to identify optimal cut-off values and the 
investigation of repeat testing strategies in people with intermediate levels.  
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Conclusion 
 
The data presented in this thesis has revealed that FC correlates well with WCS in CD 
patients and has an acceptable intra-individual variability in CD allowing one off 
samples to be of clinical utility in this setting. In addition we showed the prognostic 
value of FC in CD in remission and the potential for over investigation of new patients 
referred to the GI clinic with mildly elevated FC. Lastly our most recent dataset reveals 
no correlation between FC and serum calprotectin.  
Over the last 15 years, FC has evolved from a little known faecal biomarker to 
becoming established in routine luminal gastroenterology practice. It is a sensitive, non-
invasive marker of intestinal inflammation which has found clinical utility in the fields 
of aiding a diagnosis of IBS, suggesting a diagnosis of IBD, monitoring disease activity 
and response to treatment in IBD and assessing for post-operative recurrence in CD. 
Without any significant challengers on the horizon, I suspect the future clinical utility 
of FC in luminal gastroenterology is secure.  
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